ChiCTR2400083469 版本V1.0 版本创建时间2024/04/26 08:38:13 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400083469 

最近更新日期:

Date of Last Refreshed on:

2024-04-26 08:37:50 

注册时间:

Date of Registration:

2024-04-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于外泌体microRNA表达不同针刺方法对肌腱炎症的临床疗效观察

Public title:

The effects of circulating exosomal microRNA profiles in supraspinatus tendonitis patients receiving different acupuncture treatment: A placebo-controlled clinical trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于外泌体microRNA表达不同针刺方法对肌腱炎症的临床疗效观察

Scientific title:

The effects of circulating exosomal microRNA profiles in supraspinatus tendonitis patients receiving different acupuncture treatment: A placebo-controlled clinical tria

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

覃渝茜 

研究负责人:

覃渝茜 

Applicant:

Qin Yuxi 

Study leader:

Qin Yuxi 

申请注册联系人电话:

Applicant telephone:

+86 138 8090 8749

研究负责人电话:

Study leader's
telephone:

+86 138 8090 8749

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1582881952@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1582881952@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市温江区永宁镇八一路81号

研究负责人通讯地址:

四川省成都市温江区永宁镇八一路81号

Applicant address:

No. 81, Bayi Road, Yongning Town, Wenjiang District, Chengdu, Sichuan Province

Study leader's address:

No. 81, Bayi Road, Yongning Town, Wenjiang District, Chengdu, Sichuan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川省八一康复中心(四川省康复医院)

Applicant's institution:

Sichuan provincial Bayi Rehabilitation Center (Sichuan provincial Rehabilitation Hospital)

研究负责人所在单位:

四川省八一康复中心(四川省康复医院)

Affiliation of the Leader:

Sichuan provincial Bayi Rehabilitation Center (Sichuan provincial Rehabilitation Hospital)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CKLL-20231102

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川省八一康复中心(四川省康复医院)医学伦理委员会

Name of the ethic committee:

Ethics Committee of Sichuan provincial Bayi Rehabilitation Center (Sichuan provincial Rehabilitation Hospital)

伦理委员会批准日期:

Date of approved by ethic committee:

2023-11-22 00:00:00

伦理委员会联系人:

林贞仿

Contact Name of the ethic committee:

Lin Zhenfang

伦理委员会联系地址:

四川省成都市温江区永宁镇八一路81号

Contact Address of the ethic committee:

No. 81, Bayi Road, Yongning Town, Wenjiang District, Chengdu, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 134 8890 8713

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川省八一康复中心(四川省康复医院)

Primary sponsor:

Sichuan provincial Bayi Rehabilitation Center (Sichuan provincial Rehabilitation Hospital)

研究实施负责(组长)单位地址:

四川省成都市温江区永宁镇八一路81号

Primary sponsor's address:

No. 81, Bayi Road, Yongning Town, Wenjiang District, Chengdu, Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

四川省八一康复中心(四川省康复医院)

具体地址:

四川省成都市温江区永宁镇八一路81号

Institution
hospital:

Sichuan provincial Bayi Rehabilitation Center (Sichuan provincial Rehabilitation Hospital)

Address:

No. 81, Bayi Road, Yongning Town, Wenjiang District, Chengdu, Sichuan Province

经费或物资来源:

成都中医药大学附属医院(四川省中医医院)2023年科技发展基金课题(23TS07)

Source(s) of funding:

Science and Technology Development Fund of chengdu university of traditional Chinese medicine(2023—23TS07))

研究疾病:

冈上肌肌腱炎  

Target disease:

Supraspinatus Tendonitis,ST

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过对比冈上肌肌腱炎(Supraspinatus Tendonitis,ST)患者不同针刺手段治疗前后血清外泌体 micro RNA 表达的变化,筛选不同针刺手法针刺效应相关的关键 micro RNA。比较文献报道的 micro RNA 与本次研究发现的 micro RNA 的差异,以期探索不同针刺手法治疗 ST 的潜在调节机制。  

Objectives of Study:

Acupuncture has a long history of being used in Chinese medicine for the treatment of Supraspinatus Tendonitis. However, molecular biomarkers for diagnosis and prognosis of ST and its treatment are lacking. This study aimed to explore whether acupuncture could regulate differentially expressed exosomal miRNAs between patients with ST and healthy controls (HCs) and to identify diagnostic biomarkers that helped differentiate ST patients from HCs and identify prognostic biomarkers that helped to predict the effect of acupuncture.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

① 符合上述 ST 的诊断标准,并且为单侧发病。 ② 年龄:20-60 岁之间(包含 20、60 岁)。 ③ 就医前一月内未进行任何相关于 ST 的中西医治疗,并且未因其他原因服用镇痛药。 ④ 患者精神及认知功能正常,并能配合并完成治疗全过程,自愿加入且签署知情同意书。 ⑤ 能够接受不同针刺手法治疗,并且无相关禁忌症。

Inclusion criteria

① The diagnosis criteria of ST were met, and the disease was unilateral. ②Age: between 20 and 60 years old (including 20 and 60 years old). ③ No Chinese and western medicine treatment related to ST was performed within one month before medical treatment, and no analgesics were taken for other reasons. ④ The patient has normal mental and cognitive functions, can cooperate and complete the whole process of treatment, and voluntarily join and sign the informed consent. ⑤ Can be treated with different acupuncture techniques, and there are no related contraindications.

排除标准:

① 正在接受其他有可能会影响观察指标的治疗。 ② 有任何针刺治疗相关禁忌症;操作局部皮肤破损的患者。 ③ 妊娠或哺乳期妇女;既往有出血倾向或凝血功能障碍病史的患者。 ④ 合并心脑血管等疾病、处于偏瘫状态的患者;合并肝、肾、内分泌系统等患有严重原发性疾病的患者;继发于风湿性关节炎、类风湿性关节炎、糖尿病等全身系统性疾病的患者。 ⑤ 兼有肩部其他疾病,如骨折、脱位、肱二头肌长头肌腱炎等其他肩部软组织损伤等。

Exclusion criteria:

① Are receiving other treatments that may affect the outcome measures. ② There are any contraindications related to acupuncture treatment; Handling patients with local skin damage. ③Pregnant or lactating women; Patients with a history of bleeding or coagulopathy. ④ Patients with cardiovascular and cerebrovascular diseases and hemiplegia; Patients with severe primary diseases of liver, kidney, endocrine system, etc.; Secondary to rheumatoid arthritis, rheumatoid arthritis, diabetes and other systemic diseases. ⑤ With other shoulder diseases, such as fracture, dislocation, biceps long head tendinitis and other shoulder soft tissue injuries.

研究实施时间:

Study execute time:

From 2024-05-01 00:00:00 To 2025-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-05-01 00:00:00 To 2025-04-30 00:00:00

干预措施:

Interventions:

组别:

健康对照组(HC)

样本量:

26

Group:

health contorl group

Sample size:

干预措施:

无干预措施

干预措施代码:

HC

Intervention:

no treatment

Intervention code:

组别:

电针治疗组

样本量:

26

Group:

Electroacupuncture therapy group

Sample size:

干预措施:

电针治疗

干预措施代码:

EA

Intervention:

Electroacupuncture therapy

Intervention code:

组别:

杵针治疗组

样本量:

26

Group:

pestle needle group

Sample size:

干预措施:

杵针

干预措施代码:

PN

Intervention:

pestle needle

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

四川省八一康复中心(四川省康复医院) 

单位级别:

三甲 

Institution
hospital:

Sichuan provincial Bayi Rehabilitation Center (Sichuan provincial Rehabilitation Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血液miRNA

指标类型:

主要指标

Outcome:

Circulating exosomal microRNA

Type:

Primary indicator

测量时间点:

干预前,干预后4周

测量方法:

Measure time point of outcome:

before and after treatment (4 weeks)

Measure method:

指标中文名:

疼痛视觉模拟评分

指标类型:

次要指标

Outcome:

Visual Analogue Score,VAS

Type:

Secondary indicator

测量时间点:

干预前,干预后4周

测量方法:

Measure time point of outcome:

before and after treatment (4 weeks)

Measure method:

指标中文名:

日常生活能力评分

指标类型:

次要指标

Outcome:

Activities of Daily Living,ADL

Type:

Secondary indicator

测量时间点:

干预前,干预后4周

测量方法:

Measure time point of outcome:

before and after treatment (4 weeks)

Measure method:

指标中文名:

肩关节活动度评分

指标类型:

次要指标

Outcome:

Range of Motion, ROM

Type:

Secondary indicator

测量时间点:

干预前,干预后4周

测量方法:

Measure time point of outcome:

before and after treatment (4 weeks)

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机分配序列由一名独立统计学家使用统计学软件SAS9.1PLAN句子编辑生成,该统计学家来自于四川大学华西医学院循证医学中心,不参与该实验研究。符合纳入标准的患者通过随机和盲法分配到2个研究组(EA,PN),确保每一例患者分配到2个组的几率一致。随机分组的序列号有专门指定的一名助教负责保管隐藏,所有研究人员在最后结果完成后才能知晓相关结果。分配到有针灸治疗的针灸治疗师将被直接告知分配的组别。所有患者在分配好组别后均会被告知所分组别名称和相关干预措施。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random allocation sequence will be produced by an independent statistician via the PLAN sentences of the statistical software SAS9.1, who works in the Evidence- Based Center of the Sichuan University and is not involved in the study. The eligible patients will be randomly and blindly allocated to the two study groups (EA,PN), ensuring that each patient had a consistent probability of being assigned to all four groups. The sequence numbers of random groups are kept hidden by a special teaching assistant, and all researchers will not know the relevant results until the final results are completed. Acupuncture therapists assigned to acupuncture treatments will be informed directly of the assigned group. All patients will be informed of the group name and relevant interventions after they are assigned to the group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

None

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

no sharing

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no sharing

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有病例均采用病例记录表(Case Record Form, CRF) ,使用本院电子采集和管理系统进行数据管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-04-26 08:37:50